Herpes Zoster Treatment Market Size in 2022, Trends, SWOT analysis, Rapid growth Forecast to 2028

Herpes Zoster, also known as zoster or shingles, is a viral disease characterized by a painful skin rash with blisters in a localized area. Typically the rash occurs in a single, wide stripe either on the left or right side of the body or face. Two to four days before the rash occurs there may be tingling or local pain in the area. Otherwise there are typically few symptoms though some may have fever, headache, or feel tired. The rash usually heals within two to four weeks; however, some people develop ongoing nerve pain which can last for months or years, a condition called postherpetic neuralgia (PHN). In those with poor immune function the rash may occur widely. If the rash involves the eye, vision loss may occur.Report OverviewDue to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Herpes Zoster Treatment estimated at USD million in the year 2022, is projected to reach a revised size of USD million by 2028, growing at a CAGR of percent during the forecast period 2022-2028.The USA market for Herpes Zoster Treatment is estimated to increase from USD million in 2022 to reach USD million by 2028, at a CAGR of percent during the forecast period of 2023 through 2028.The China market for Herpes Zoster Treatment is estimated to increase from USD million in 2022 to reach USD million by 2028, at a CAGR of percent during the forecast period of 2023 through 2028.The Europe market for Herpes Zoster Treatment is estimated to increase from USD million in 2022 to reach USD million by 2028, at a CAGR of percent during the forecast period of 2023 through 2028.The global key companies of Herpes Zoster Treatment include Roche, Novartis, Merck, GlaxoSmithKline, Abbott Laboratories, Astellas Pharma, Bausch Health Companies, Teva Pharmaceutical and Foamix Pharmaceuticals, etc. In 2021, the global top five players had a share approximately percent in terms of revenue.